Rib-X Pharma (RIBX) Cuts IPO Price from $12-$14 to $6-$7/Share

May 8, 2012 8:24 AM EDT Send to a Friend
Get Alerts RIBX Hot Sheet
Trade RIBX Now!
Join SI Premium – FREE
According to an amended S-1 filing with the SEC Tuesday morning, Rib-X Pharmaceuticals (Nasdaq: RIBX) now expects to price 10 million shares of common stock in the range of $6-$7 per share for its initial public offering. The company had previously expected to sell about 5.77 million common shares in the range of $12-$14 per share.

Rib-X plans to list on the NASDAQ exchange under the symbol "RIBX."

The offering is being made through Deutsche Bank, William Blair, Lazard and Needham.

Rib-X is a biopharmaceutical company developing new antibiotics to provide superior coverage, safety and convenience for the treatment of serious and life-threatening infections. The company's proprietary drug discovery platform, which is based on Nobel Prize-winning science, provides an atomic-level, three-dimensional understanding of interactions between drug candidates and their bacterial targets and enables Rib-X to systematically engineer antibiotics with enhanced characteristics.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

IPOs

Related Entities

Deutsche Bank, William Blair, Needham & Company, Lazard, S1

Add Your Comment